SHPMY SHANGHAI PHARMACEU
- 7.175
- -0.335-4.46%
SHANGHAI PHARMACEU News
Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved
Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%
Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) attributable profit rose 1.62% year over year to 1.54 billion yuan in the first quarter from 1.52 billion yuan, according to separate filings
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Shanghai Pharmaceutical (02607.HK) net profit of 1,542 billion yuan in the first quarter increased 1.62% year-on-year
Gelonghui, April 26 | Shanghai Pharmaceutical (02607.HK) announced that in the first quarter of 2024, during the reporting period, the company's main business grew steadily, achieving operating revenue of 70.153 billion yuan (currency is RMB, same below), an increase of 5.93% over the previous year. Among them, the pharmaceutical industry achieved sales revenue of 6.944 billion yuan, a year-on-year decrease of 10.98%; the pharmaceutical business achieved sales revenue of 63.209 billion yuan, an increase of 8.19% over the previous year. During the reporting period, the company achieved net profit attributable to shareholders of listed companies of 1,542 billion yuan, an increase of 1.62% over the previous year. Among them, the industrial business contributed profit
上海醫藥：2024年第一季度報告
上海醫藥：2023 年年報
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
Damo: Target price for Shanghai Pharmaceuticals “gain” rating reduced to HK$17
Morgan Stanley released a research report stating that it lowered the target price of Shanghai Pharmaceuticals (02607) by 5.6%, from HK$18 to HK$17, and lowered the company's profit forecast for 2024-2030 by 2%-9%. The main reason was the decline in sales in the manufacturing sector, but the rating still “increased”, mainly due to the complete integration of the platform (manufacturing, distribution, retail) to provide a synergy effect.
Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17
DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.
Private Companies in Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 4.8% Last Week
Key Insights Significant control over Shanghai Pharmaceuticals Holding by private companies implies that the general public has more power to influence management and governance-related decisions Th
UBS: Target price of HK$14.9 for the initial “buy” rating for Shanghai pharmaceuticals
UBS released a research report stating that it initially gave Shanghai Pharmaceuticals (02607) a “buy” rating, with a target price of HK$14.9. Shanghai Pharmaceutical is the second-largest pharmaceutical distributor in China. It accounts for about 9.5% of the market share in 2022. It is optimistic that it has the potential to have differentiated one-stop distribution services and its own pipeline for the production of new drugs. It is predicted that the compound annual growth rate of revenue and profit will reach 10% and 10.6% from 2024 to 2026. Potential positive catalysts include approval of new drugs, strong drug sales expectations, and signing new exclusive distribution agreements with international pharmaceutical companies.
Shanghai Pharmaceutical (02607.HK) held a board meeting on April 26 to approve the first quarter results
Gelonghui, April 16 | Shanghai Pharmaceutical (02607.HK) announced that the board of directors meeting will be held on April 26, 2024 (Friday) to approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Research Report Nuggets丨Zheshang Securities: Shanghai Pharmaceuticals' 23-year profits are under pressure in the short term, optimistic about the 24-year inflection point
According to the Zheshang Securities Research Report, Shanghai Pharmaceutical (601607.SH)'s revenue grew steadily in 2023, and profits were under pressure in the short term. It is optimistic about the 24-year inflection point and maintains an “gain” rating. The company continued to make efforts in innovative distribution business, deepened sales cooperation with overseas MNC, and achieved a higher growth rate than the sector as a whole. In 2023, the total number of imported products added by the company reached 29, and the CSO business revenue was 2.9 billion yuan, or about 50% by YOY. Looking ahead, the bank is optimistic about the continued and rapid expansion of the company's commercial side in high-value-added and emerging distribution businesses such as innovative distribution and non-pharmaceutical distribution, and the company is optimistic about the north and south
Shanghai Pharmaceutical (601607.SH): Rabeprazole sodium enteric tablets passed generic drug consistency evaluation
Gelonghui, April 10 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for rabeprazole sodium enteric tablets. The drug passed the generic drug consistency evaluation. Rabeprazole sodium enteric tablets are mainly used to treat gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, and Zhuo-Ai syndrome. It is used as an adjunct to treat patients with gastric ulcer or duodenal ulcer to eradicate Helicobacter pylori, by eISaiCo. , Ltd. R&D, first listed in Japan in 1997.
Shanghai Pharmaceutical (601607.SH): Lorazepam tablets passed generic drug consistency evaluation
Gelonghui, April 9 | Shanghai Pharmaceutical (601607.SH) announced that its holding subsidiary Shandong Xinyi Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for lorazepam tablets. The drug passed the consistent evaluation of the quality and efficacy of generic drugs. Lorazepam tablets are mainly used to treat anxiety disorders or for short-term treatment of anxiety symptoms and anxiety associated with depression. They were developed by VALEANTINTL and first marketed in the US in 1977.
Shanghai Pharmaceuticals: Bulk Raw Material Imports May Face Short-Term Risks >2607.HK
Shanghai Pharmaceuticals: Bulk Raw Material Imports May Face Short-Term Risks >2607.HK
Shanghai Pharmaceuticals: To Continue Strengthening R&D Investments >2607.HK
Shanghai Pharmaceuticals: To Continue Strengthening R&D Investments >2607.HK
Shanghai Pharmaceuticals 2023 Rev CNY260.295B Vs. CNY231.98B >2607.HK
Shanghai Pharmaceuticals 2023 Rev CNY260.295B Vs. CNY231.98B >2607.HK
Analysis
Price Target
No Data
